

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Irvin et al ATTY. DOCKET NO.: 113190-063  
SERIAL NO: Unknown GROUP ART UNIT: Unknown  
FILED: Herewith EXAMINER: Unknown  
INVENTION: "PSEUDOMONAS TREATMENT COMPOSITION AND METHOD"

Assistant Commissioner of Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT ACCOMPANYING  
THE FILING OF AN APPLICATION**

SIR:

Please enter the following Preliminary Amendment in the above-identified patent application prior to examination.

**IN THE SPECIFICATION**

Please replace the paragraph at page 1, lines 1-4, with the following rewritten paragraph:

***Pseudomonas Treatment Composition and Method***

The present application is a continuation of U.S. Patent Application No. 09/329,884 filed on June 11, 1999.

This application claims priority to U.S. Provisional Application Serial No. 60/089,155 filed June 12, 1998, which is hereby incorporated by reference.

Please replace the paragraph at page 13, lines 26-31, with the following rewritten paragraph:

A.BY/SnJ mice were used as they are less resistant to *P. aeruginosa* infection than other mouse strains. Weight: 18-20 grams; age: 10 weeks. K122-4 truncated pilin (Fig. 1A) was administered intraperitoneally to A.BY/SnJ mice 15 minutes prior to the mice being challenged

intraperitoneally with PAK wildtype at 3LD<sub>50</sub>. Mice were monitored on a hourly basis between 16 and 48 hours. As seen in Figure 9, percent survival was dose dependent within the range of pilin protein amounts tested.

After page 15, please add pages 1-9 of the sequence listing attached hereto as Exhibit A.

### **IN THE CLAIMS**

Please add Claim 20 as follows:

Claim 20 (newly added) A method of treating or preventing infection by *Pseudomonas aeruginosa* comprising administering a pharmaceutically acceptable amount of an isolated pilin peptide having the amino acid sequence set forth in SEQ ID Nos. 4, 6, 8, or 10.

Please cancel Claims 1-19 without prejudice or disclaimer.

### **REMARKS**

Applicants respectfully request that the Preliminary Amendment be entered prior to the examination of the above-identified application.

Applicants submit that the Preliminary Amendment makes changes to the Specification for priority purposes and in accordance with those changes made to U.S. Patent Application No. 09/329,884. Claim 20 has been newly added for reconsideration upon examination.

Accordingly, Applicants respectfully request early and favorable consideration of the present application.

Respectfully submitted,



Robert M. Barrett (Reg. No. 30,142)  
BELL, BOYD & LLOYD LLC  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
(312) 807-4204

ATTORNEY FOR APPLICANTS

384858v1/D

## APPENDIX

Please replace the paragraph at page 1, lines 1-4, with the following rewritten paragraph:

### ***Pseudomonas Treatment Composition and Method***

The present application is a continuation of U.S. Patent Application No. 09/329,884 filed on June 11, 1999.

This application claims priority to U.S. Provisional Application Serial No. 60/089,155 filed June 12, 1998, which is hereby incorporated by reference.

Please replace the paragraph at page 13, lines 26-31, with the following rewritten paragraph:

A.BY/SnJ mice were used as they are less resistant to *P. aeruginosa* infection than other mouse strains. Weight: 18-20 grams; age: 10 weeks. K122-4 truncated pilin (Fig. 1A) was administered intraperitoneally to A.BY/SnJ mice 15 minutes prior to the mice being challenged intraperitoneally with PAK wildtype at 3LD<sub>50</sub>. Mice were monitored on a hourly basis between 16 and 48 hours. As seen in Figure 9, percent survival was dose dependent within the range of pilin protein amounts tested.